Recce Pharmaceuticals Ltd (RCE) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.550x

Based on the latest financial reports, Recce Pharmaceuticals Ltd (RCE) has a cash flow conversion efficiency ratio of 0.550x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-10.23 Million ≈ $-7.24 Million USD) by net assets (AU$-18.62 Million ≈ $-13.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Recce Pharmaceuticals Ltd balance sheet independence to measure how much of total assets are equity-financed.

Recce Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Recce Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check RCE total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Recce Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Recce Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
MFC Asset Management Public Company Limited BK:MFC	0.008x
ZOOZ Power Ltd. Ordinary Shares NASDAQ:ZOOZ	72.087x
Blink Charging Co NASDAQ:BLNK	0.011x
Alan Allman Associates SA PA:AAA	0.339x
Life Settlement Assets PLC LSE:LSAA	0.123x
Afarak Group Oyj HE:AFAGR	0.001x
Panelsan Cati Cephe Sistemleri Sanayi ve Ticaret AS IS:PNLSN	0.023x
Tripar Multivision Plus JK:RAAM	0.042x

Annual Cash Flow Conversion Efficiency for Recce Pharmaceuticals Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of Recce Pharmaceuticals Ltd from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see RCE stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$-3.05 Million ≈ $-2.16 Million	AU$-20.44 Million ≈ $-14.46 Million	6.698x	+390.36%
2024-06-30	AU$-9.52 Million ≈ $-6.74 Million	AU$-13.01 Million ≈ $-9.20 Million	1.366x	-72.13%
2023-06-30	AU$-2.59 Million ≈ $-1.83 Million	AU$-12.69 Million ≈ $-8.98 Million	4.901x	+647.26%
2022-06-30	AU$10.06 Million ≈ $7.12 Million	AU$-9.01 Million ≈ $-6.38 Million	-0.896x	-133.73%
2021-06-30	AU$20.50 Million ≈ $14.51 Million	AU$-7.86 Million ≈ $-5.56 Million	-0.383x	+76.73%
2020-06-30	AU$2.31 Million ≈ $1.64 Million	AU$-3.81 Million ≈ $-2.69 Million	-1.646x	-125.56%
2019-06-30	AU$-405.60K ≈ $-286.99K	AU$-2.61 Million ≈ $-1.85 Million	6.440x	+358.34%
2018-06-30	AU$694.91K ≈ $491.70K	AU$-1.73 Million ≈ $-1.23 Million	-2.493x	+41.10%
2017-06-30	AU$590.14K ≈ $417.56K	AU$-2.50 Million ≈ $-1.77 Million	-4.233x	-825.16%
2016-06-30	AU$3.51 Million ≈ $2.49 Million	AU$-1.61 Million ≈ $-1.14 Million	-0.458x	-628.29%
2015-06-30	AU$4.71 Million ≈ $3.34 Million	AU$-296.14K ≈ $-209.54K	-0.063x	+69.36%
2014-06-30	AU$-55.74K ≈ $-39.44K	AU$11.43K ≈ $8.09K	-0.205x	--

About Recce Pharmaceuticals Ltd

AU:RCE Australia Biotechnology

Market Cap

$79.46 Million

AU$112.30 Million AUD

Market Cap Rank

#20078 Global

#659 in Australia

Share Price

AU$0.38

Change (1 day)

+0.00%

52-Week Range

AU$0.35 - AU$0.71

All Time High

AU$1.68